10:24 AM EDT, 07/18/2024 (MT Newswires) -- Phathom Pharmaceuticals ( PHAT ) said Thursday the US Food and Drug Administration approved Voquezna tablets for the relief of heartburn related to non-erosive gastroesophageal reflux disease in adults.

Voquezna is also approved to treat all severities of erosive esophagitis and in combination with antibiotics for the eradication of helicobacter pylori infection, the company said.

Phathom Pharmaceuticals ( PHAT ) shares fell 3.8% in recent trading Thursday.

Price: 11.65, Change: -0.46, Percent Change: -3.80